



HAL
open science

Kinetics and pattern of viral excretion in biological specimens of two MERS-CoV cases

J. Poissy, A. Goffard, E. Parmentier-Decrucq, R. Favory, M. Kauv, E. Kipnis,
D. Mathieu, B. Guéry

► **To cite this version:**

J. Poissy, A. Goffard, E. Parmentier-Decrucq, R. Favory, M. Kauv, et al.. Kinetics and pattern of viral excretion in biological specimens of two MERS-CoV cases. *Journal of Clinical Virology*, 2014, 61 (2), pp.275-278. 10.1016/j.jcv.2014.07.002 . hal-02266760

HAL Id: hal-02266760

<https://hal.science/hal-02266760>

Submitted on 3 Jan 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Short Communication

Kinetics and pattern of viral excretion in biological specimens of two MERS-CoV cases



J. Poissy^{a,*}, A. Goffard^{b,c}, E. Parmentier-Decrucq^a, R. Favory^a, M. Kouv^a, E. Kipnis^{d,e,f,g}, D. Mathieu^a, B. Guery^{d,e,f,g,h}, The MERS-CoV Biology Group¹

^a Pôle de Réanimation, Hôpital Roger Salengro, Centre Hospitalier Régional et Universitaire de Lille, Université de Lille 2, Lille Cedex, France

^b Laboratoire de Virologie, Centre de Biologie Pathologie, Centre Hospitalier Régional et Universitaire de Lille, Université de Lille 2, Lille Cedex, France

^c Molecular & Cellular Virology of Hepatitis C, Center for Infection & Immunity of Lille (CIIL), Inserm U1019, CNRS UMR8204, Université Lille Nord de France, F-59000 Lille, France

^d Host-Pathogen Translational Research Group, Université de Lille 2, Lille Cedex, France

^e Centre National de la Recherche Scientifique, Unité Mixte de Recherche 8204, F-59021 Lille, France

^f Institut National de la Santé et de la Recherche Médicale, U1019, F-59019 Lille, France

^g Département d'anesthésie-réanimation, Centre Hospitalier Régional et Universitaire de Lille, Lille Cedex, France

^h Service de maladies infectieuses, Centre Hospitalier Régional et Universitaire de Lille, Lille Cedex, France

ARTICLE INFO

Article history:

Received 19 April 2014

Received in revised form 25 June 2014

Accepted 4 July 2014

Keywords:

Coronavirus

MERS-CoV

RNA detection

Kinetic

Respiratory tract infection

ABSTRACT

Background: Middle East respiratory syndrome coronavirus (MERS-CoV) is an emerging coronavirus involved in severe acute respiratory distress syndrome (ARDS) and rapid renal failure. Hospital outbreak and nosocomial transmission were reported, however, several issues remain on the viral excretion course.

Objectives: Describe the kinetics and pattern of viral excretion in two infected patients.

Study design: After the initial diagnosis, blood, urine, rectal and respiratory samples were collected regularly, aliquoted and stored at -80°C . Real-time reverse transcriptase polymerase chain reaction assay targeted the UpE and Orf1a regions of the MERS-CoV genome.

Results: In patient 1, who died of refractory ARDS and renal failure, MERS-CoV RNA was detected in pharyngeal and tracheal swabs, as well blood samples and urine samples until the 30th day. Rectal swabs were negative. Patient 2 also developed multiple-organ failure, but survived, with persisting renal insufficiency (creatinine clearance at 30 mL/min) and persistent interstitial syndrome albeit weaned off mechanical ventilation and no longer requiring oxygen. Tracheal aspirations were positive until the 33rd day, while nasopharyngeal swabs were negative. All other biological samples were negative.

Discussion: Lower respiratory tract excretion of MERS-CoV could be observed for more than one month. The most severely ill patient presented an expression of the virus in blood and urine, consistent with a type-1 interferon mediated immunological response impaired in patient 1, but developed by patient 2. These results suggest that infection control precautions must be adequately evaluated in clinical wards and laboratories exposed to MERS-CoV.

© 2014 Elsevier B.V. All rights reserved.

1. Background

Middle East respiratory syndrome coronavirus (MERS-CoV) is an emerging virus which appeared in the Arabian Peninsula in June

2012 [1]. The MERS-CoV belongs to the order of *Nidovirales*, the family of *Coronaviridae* and the genus of *Betacoronavirus* [2]. Coronaviruses are large enveloped single-stranded RNA viruses that can infect birds and mammals [3]. Since the mid-1960s, human coronaviruses were known for causing common cold (HCoV-229 and OC43), and in the 2000s they were found to cause bronchiolitis (NL63) and pneumonia mainly during the SARS epidemic (HKU-1 and SARS-CoV) [4]. Although asymptomatic infections have been reported, the MERS-CoV causes severe pneumonia with acute respiratory distress and multiple-organ failure leading to a high mortality rate [5]. A recently published analysis showed that patients with severe disease had at least one underlying

* Corresponding author. Tel.: +33 650862354.

E-mail address: julien_poissy@hotmail.fr (J. Poissy).

¹ MERS-CoV Biology Group: K. Alidjinou, L. Bocket, A. Dewilde, I. Engelmann, D. Hober, M. Lazrek, B. Prévost (Virology, Lille); S. Behillil, V. Enouf, S. Van der Werf (Institut Pasteur, National Reference Center for Influenza Viruses and Unit of Molecular Genetics of RNA Viruses, Paris).

condition, including diabetes, hypertension, chronic cardiac disease and chronic renal disease [6]. This study also showed that both community-acquired and health care associated MERS-CoV infections occur in patients with chronic comorbid conditions [7]. As of 11 June, 699 laboratory-confirmed cases of human infection with MERS-CoV have been reported to the World Health Organization, including at least 209 deaths [8]. Several cases had been described in other countries than the Arabian Peninsula but all patients had a history of travel to the Middle East, except secondary cases described in UK and France [9,10].

MERS-CoV diagnosis is based on viral RNA detection in samples collected from the lower respiratory tract such as tracheal swabs, induced sputum, endotracheal aspirates, bronchoscopic aspirates or broncho-alveolar lavage samples, to avoid contamination by upper respiratory tract flora. Furthermore, detection of viral RNA in samples from the upper respiratory tract such as nasal and throat swabs, or nasopharyngeal aspirates, may remain negative while lower respiratory tract samples are positive [11]. To date, only few studies have reported detection of MERS-CoV RNA in blood, urine and stool samples [11,12]. However, many questions remain unsolved, and recently it was underlined that additional data are needed to document the natural history of the infection, the excretion pattern and viral kinetics during infection, and the best samples for optimal Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) yield [6].

We report a full description of MERS-CoV RNA detection data obtained in samples collected from two infected patients admitted to a French hospital in May, 2013. MERS-CoV RNA was detected using a RT-PCR assay in upper respiratory tract samples (nasal swabs), lower respiratory tract samples (induced sputum, endotracheal aspiration or bronchoscopic sampling after bronchoalveolar lavage), whole blood, and urine samples.

2. Objectives

This study was designed to describe the kinetics of viral excretion during MERS-CoV infection and analyze the potential correlation with either clinical and/or immunological patterns.

3. Study design

Samples were collected according to the ISARIC protocol's recommendations [13]: the initial diagnosis was confirmed by RT-PCR performed on lower respiratory tract, whole blood or urine samples. Following diagnosis, samples from these same sites were regularly collected as well as rectal, nasal, and pharyngeal swabs. Samples were aliquoted and stored at -80°C .

Nucleic acid extractions from specimens were performed using the NucleoSpin Dx Virus[®] or NucleoSpin[®] RNA blood Mini kits (Macherey-Nagel GmbH & Co. KG, Düren, France) according to the manufacturer's instructions. For respiratory tract aspirates, a pretreatment with proteinase K (5 mg/mL for 10 min at 70°C) or Digest-EUR[®] (Eurobio, Courtaboeuf, France) was applied to reduce viscosity. Sigma viral RNA, 10 ng per assay (Sigma-Aldrich Chemie S.a.r.l., L'Isle d'Abeau, France) was included as a control for the extraction procedure and the absence of inhibitors.

Extracted RNA was tested by real-time RT-PCR assay targeting the UpE and Orf1a regions of the MERS-CoV genome as previously described on a LightCycler 480 real-time PCR system (Roche, Courtaboeuf, France) [2,14]. Sample quality was assessed by real-time RT-PCR targeting the GAPDH house-keeping gene. Positive control for UpE and Orf1a real-time RT-PCR was an in vitro transcribed RNA, combining the sequences of the Orf1a gene (from nucleotide 11,172 to nucleotide 11,414) and the UpE gene (from

Table 1

Virus detection in samples collected from patient 1.

Specimen	Date Day	May 14 20	May 16 22	May 21 27	May 23 29	May 24 30
Nasal swab	UpE (Cp)	neg	37.3	neg	40	neg
	Orf1a (Cp)	neg	neg	neg	neg	neg
Pharyngeal swab	UpE (Cp)	35.2	34.7	32.5	38.3	40
	Orf1a (Cp)	35.8	34.7	33.6	38.4	40
Tracheal swab	UpE (Cp)	24.1	26.7	27.4	36.5	34.5
	Orf1a (Cp)	25.5	26.6	28.4	36.0	35.3
Whole blood	UpE (Cp)	nd	nd	29.2	32.5	31.7
	Orf1a (Cp)	nd	nd	32.1	32.3	31.8
Urine	UpE (Cp)	34.5	35.8	31.7	32.3	38.1
	Orf1a (Cp)	34.6	35.7	33.3	31.5	37.4
Rectal swab	UpE (Cp)	neg	37.7	neg	neg	neg
	Orf1a (Cp)	neg	neg	neg	neg	neg

Day: days after the onset of illness; Cp: cycle point; neg: negative; nd: not determined.

nucleotide 27,357 to nucleotide 27,760) as the positive strand, designed based on the first published sequence of MERS-CoV [15]. According to the recommendations of Corman and colleagues, the diagnosis of MERS-CoV infection was performed by detection of two MERS-CoV genes: UpE for screening and Orf1a for confirmation [2,14]. Thus, a biological sample was considered positive if both targets were positive.

4. Results

A full clinical overview of these patients was previously published [11]. Briefly, patient 1, a 64-year-old man, had undergone renal transplantation in 1998 for renal failure secondary to diabetes. Regular medications included mycophenolate mofetil, ciclosporin, and prednisone. Clinical symptoms began on April 22 upon returning from travel to Dubai; he was transferred to the Lille University Teaching Hospital intensive care unit (ICU) and intubated on April 30. On May 8, the patient required extracorporeal membrane oxygenation (ECMO) support, and died on May 28 from refractory multiple organ failure.

Patient 2, a 51-year-old man, was admitted on April 26. His medical history included a histamine-induced angioedema treated with systemic corticosteroid therapy. He shared patient 1's room from April 26 to April 29. On May 8, he presented with asthenia, myalgia, and cough. On May 12, he was intubated and transferred to the Lille University Teaching Hospital ICU. The patient required ECMO support on May 14 for refractory hypoxemia despite optimal treatment. The patient was successfully weaned off ECMO on June 17. On July 2, percutaneous tracheotomy was performed. He required 3 days of intermittent haemodialysis per week until mid-July.

As previously described, for patient 1, MERS-CoV RNA was detected for the first time in a broncho-alveolar lavage sample two days after the onset of symptoms [11]. Afterwards, between the 13th and the 30th day after the onset of illness, MERS-CoV RNA was detected in each pharyngeal and tracheal swab obtained. During the same period, MERS-CoV RNA was not detected in nasal swabs. MERS-CoV RNA detection was also tested in urine, blood samples and rectal swabs. Viral RNA was detected in blood samples from the 13th to the 30th day after the onset of illness. Urine samples were collected from the 20th to the 30th day after the onset of illness and MERS-CoV RNA was always detected. Detection of MERS-CoV RNA in rectal swabs always remained negative. These results are summarized in Table 1 with corresponding cycle points for UpE and Orf1a.

For patient 2, MERS-CoV diagnosis was confirmed after detection of the viral RNA from an induced sputum sample collected on

Table 2
Virus detection in samples collected from patient 2.

Specimen	Date Day	May 14 6	May 17 9	May 20 12	May 23 15	May 24 16	May 31 23	June 3 26	June 5 28	June 7 30	June 10 33
Nasal swab	UpE (Cp)	38.9	37.6	neg	neg	neg	neg	neg	neg	neg	neg
	Orf1a (Cp)	neg	neg	neg	neg	neg	neg	neg	neg	neg	neg
Pharyngeal swab	UpE (Cp)	37.8	38.8	neg	neg	neg	neg	neg	neg	neg	neg
	Orf1a (Cp)	neg	neg	neg	neg	neg	neg	neg	neg	neg	neg
Tracheal swab	UpE (Cp)	26.3	23.3	24.7	34.9	28.6	28.7	36.2	36.2	32.8	36.9
	Orf1a (Cp)	28.8	25.8	26.8	34.5	30.5	29.8	36.4	35.5	34.3	36.5
Whole blood	UpE (Cp)	nd	neg	neg	neg	neg	neg	neg	neg	nd	nd
	Orf1a (Cp)	nd	neg	neg	neg	neg	neg	neg	neg	nd	nd
Urine	UpE (Cp)	neg	neg	neg	neg	neg	neg	neg	neg	neg	nd
	Orf1a (Cp)	neg	neg	neg	neg	neg	neg	neg	neg	neg	nd
Rectal swab	UpE (Cp)	37.5	38.8	neg	neg	neg	neg	neg	neg	nd	neg
	Orf1a (Cp)	neg	neg	neg	neg	neg	neg	neg	neg	nd	neg

Day: days after the onset of illness; Cp: cycle point; neg: negative; nd: not determined.

day 3 after the onset of illness [11]. In the following days, MERS-CoV RNA was positive in endotracheal aspirates collected from the 6th to the 33rd day after the onset and illness. After the 33rd day of the onset of illness, viral RNA was no longer in tracheal swabs. Detection of MERS-CoV RNA in all other biological samples tested was negative throughout the course of infection. These results are summarized in Table 2.

5. Discussion

This report describes the timecourse of MERS-CoV RNA detection by RT-PCR in different biological samples collected from two patients with different outcomes.

In both cases viral RNA was detected in endotracheal aspirates, up to 33 days after the onset of illness for one patient. Our data confirm previous studies showing that the detection of viral RNA from oronasal swabs can be negative even though MERS-CoV RNA was detected in tracheobronchial aspirates throughout the course of infection in case of fatal outcome [12]. It has been previously reported that samples collected from the lower respiratory tract were more relevant for diagnosis of MERS-CoV infection [9,11,12]. Here, we show that these samples are also more relevant for the follow-up of MERS-CoV infection. Since respiratory viral excretion was sustained for more than one month after the onset of infection, standard, contact, and airborne precautions must remain unchanged and applied correctly to avoid nosocomial transmission, which is still possible as described in several countries, including transmission to healthcare professionals [11,16]. However, the question of MERS virus viability in different samples, and hence infectivity of these samples remains unanswered. By comparison with other respiratory viruses, in immunocompetent patients, *Influenzavirus* RNA detection was detected for a few days while a long-term detection of coronavirus RNA has been shown previously in severe immunocompromised patients [17,18]. Detection of human coronaviruses RNA in stool samples has been observed [19,20] but, excepted for SARS-CoV, the duration of the detection of human coronaviruses RNA in stool samples of patients was never studied [21,22]. Human coronaviruses RNA was never detected in urine of patients with exception for SARS-CoV RNA (Lau et al. [22]).

For the first patient, viral RNA was detected in whole blood up to 4 days before his death. Previously, viral RNA was detected in plasma samples only once but not in the blood cell pellet [11]. Another study reported the absence of MERS-RNA detection in serum samples [12]. During the previous SARS-CoV outbreak, virus RNA was detected in the plasma and sera of infected patients at

the acute phase of infection [23,24]. Thus, SARS-CoV and MERS-CoV can circulate in whole blood, but further studies are needed to determine if MERS-CoV is simply excreted in serum, plasma or if it can infect white blood cells.

In this study, we did not detect MERS-CoV RNA in rectal swabs, but stool samples seem to be more relevant samples for detection of viral RNA in the digestive tract [12].

MERS-CoV RNA was detected in urine samples collected from patient 1 but not from patient 2. Detection of viral RNA in urine samples has previously been described [12] but only at the onset of infection, with low quantitative amounts of virus. Here, we describe long-term excretion of MERS-CoV in urine samples in a patient with renal failure. MERS-CoV has a tropism for human kidney cells that could explain renal failure [25]. Interestingly, both patients developed renal failure requiring renal replacement, but the virus was only found in the urinary tract of the viremic patient. However, the relationship between the virus renal tropism and the pathophysiology of the renal failure is not so clear, and the questions of independent renal viral replication and/or active urinary secretion of the virus remain unsolved. Of note, the detection of viral RNA in one dialysate sample was negative, but it is difficult to conclude in only one sample.

The two cases of MERS-CoV infections presented in this report had different outcomes and different MERS-CoV detection profiles. Patient 2 had a favorable outcome and viral RNA was not detected in whole blood or urine samples suggesting that MERS-CoV infection remained localized to the respiratory tract. Patient 1 died of complications and up to 4 days prior to death, viral RNA was detected in pharyngeal and tracheal swabs, whole blood and urines, suggesting disseminated viral infection. Likewise, a previous study describing a fatal outcome, reported that MERS-CoV RNA was detected in samples collected from the lower respiratory tract, in whole blood, and in urine and stool samples [12]. Taken together, these observations suggest that MERS-CoV can disseminate systemically as previously described for SARS-CoV during the 2003 outbreak [23,26].

We recently reported that these two patients exhibited different inflammatory response profiles. Patient 1 compared to patient 2 could not promote type-1 interferon (IFN), and exhibited higher serum concentrations of CXCL10 and IL-10. Combining these host-response data with the viral excretion data we report here. It could be hypothesized that type-1 interferon mediated response triggered by MERS-CoV may limit the viral disease to the lung and prevent systemic dissemination and viremia [27]. This could support the rationale to propose IFN treatment as suggested by experimental data [28,29].

6. Conclusion

Our data showing that MERS-CoV infection involves multiple organs supports the strict and prolonged application of standard, contact, and airborne precautions to patients with suspected or confirmed MERS-CoV infection, and for individual protection of healthcare professionals during any care processes or procedures. Likewise, protection is also recommended for laboratory workers in the processing of all biological samples collected from such patients.

Funding

Samples and viral detection was part of routine clinical management of the patients in the context of MERS-CoV performed in the Lille University Teaching Hospital, therefore no specific funding was necessary.

Competing interests

The authors declare no competing interests concerning the topics in this article.

Ethical approval

All the results described in this study come from routine biological samples obtained during the course of routine clinical management of the patients, and now part of a biological collection, registered and declared in compliance with French law. Patients' spouses provided written informed consent for the use of data and samples for research and reporting purposes.

References

- Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. *N Engl J Med* 2012;367:1814–20.
- Corman VM, Eckerle I, Bleicker T, Zaki A, Landt O, Eschbach-Bludau M, et al. Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. *Euro surveillance: bulletin European sur les maladies transmissibles = European Communicable Disease Bulletin* 2012;17.
- Woo PC, Lau SK, Huang Y, Yuen KY. Coronavirus diversity, phylogeny and interspecies jumping. *Exp Biol Med (Maywood)* 2009;234:1117–27.
- Dijkman R, van der Hoek L. Human coronaviruses 229E and NL63: close yet still so far. *J Formos Med Assoc = Taiwan yi zhi* 2009;108:270–9.
- The Who Mers-Cov Research G. State of knowledge and data gaps of Middle East respiratory syndrome coronavirus (MERS-CoV) in humans. *PLoS Curr* 2013;5.
- Assiri A, Al-Tawfiq JA, Al-Rabeeh AA, Al-Rabiah FA, Al-Hajjar S, Al-Barrak A, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. *Lancet Infect Dis* 2013;13:752–61.
- Arabi YM, Arifi AA, Balkhy HH, Najm H, Aldawood AS, Ghabashi A, et al. Clinical course and outcomes of critically ill patients with Middle East respiratory syndrome coronavirus infection. *Ann Intern Med* 2014.
- Newsroom C. CDC announces first case of Middle East Respiratory Syndrome coronavirus infection (MERS) in the United States. CDC; 2014.
- Birmingham A, Chand MA, Brown CS, Aarons E, Tong C, Langrish C, et al. Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012. *Euro surveillance: bulletin European sur les maladies transmissibles = European Communicable Disease Bulletin* 2012;17:20290.
- Gulland A. Two cases of novel coronavirus are confirmed in France. *BMJ* 2013;346:f3114.
- Guery B, Poissy J, el Mansouf L, Sejourne C, Ettahar N, Lemaire X, et al. Clinical features and viral diagnosis of two cases of infection with Middle East respiratory syndrome coronavirus: a report of nosocomial transmission. *Lancet* 2013;381:2265–72.
- Drosten C, Seilmaier M, Corman VM, Hartmann W, Scheible G, Sack S, et al. Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection. *Lancet Infect Dis* 2013;13:745–51.
- 3 IwG. ISARIC/WHO Severe Acute Respiratory Infection Biological Sampling Study [17th] May 2013. Version 2.5.3.
- Corman VM, Muller MA, Costabel U, Timm J, Binger T, Meyer B, et al. Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections. *Euro surveillance: bulletin European sur les maladies transmissibles = European Communicable Disease Bulletin* 2012;17.
- van Boheemen S, de Graaf M, Lauber C, Bestebroer TM, Raj VS, Zaki AM, et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. *mBio* 2012;3.
- Assiri A, McGeer A, Perl TM, Price CS, Al Rabeeh AA, Cummings DA, et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. *N Engl J Med* 2013;369:407–16.
- Waiboci LW, Lebo E, Williamson JM, Mwitwi W, Kikwai GK, Njuguna H, et al. Viral shedding in patients infected with pandemic influenza A (H1N1) virus in Kenya, 2009. *PLoS ONE* 2011;6:e20320.
- Milano F, Campbell AP, Guthrie KA, Kuypers J, Englund JA, Corey L, et al. Human rhinovirus and coronavirus detection among allogeneic hematopoietic stem cell transplantation recipients. *Blood* 2010;115:2088–94.
- Rovida F, Campanini G, Piralla A, Adzasehoun KM, Sarasini A, Baldanti F. Molecular detection of gastrointestinal viral infections in hospitalized patients. *Diagn Microbiol Infect Dis* 2013;77:231–5.
- Jevnik M, Steyer A, Zrim T, Pokorn M, Mrvic T, Grosek S, et al. Detection of human coronaviruses in simultaneously collected stool samples and nasopharyngeal swabs from hospitalized children with acute gastroenteritis. *Virology* 2013;10:46.
- Liu W, Tang F, Fontanet A, Zhan L, Zhao QM, Zhang PH, et al. Long-term SARS coronavirus excretion from patient cohort, China. *Emerg Infect Dis* 2004;10:1841–3.
- Lau SK, Che XY, Woo PC, Wong BH, Cheng VC, Woo GK, et al. SARS coronavirus detection methods. *Emerg Infect Dis* 2005;11:1108–11.
- Drosten C, Gunther S, Preiser W, van der Werf S, Brodt HR, Becker S, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. *N Engl J Med* 2003;348:1967–76.
- Grant PR, Garson JA, Tedder RS, Chan PK, Tam JS, Sung JJ. Detection of SARS coronavirus in plasma by real-time RT-PCR. *N Engl J Med* 2003;349:2468–9.
- Eckerle I, Muller MA, Kallies S, Gotthardt DN, Drosten C. In-vitro renal epithelial cell infection reveals a viral kidney tropism as a potential mechanism for acute renal failure during Middle East respiratory syndrome (MERS) coronavirus infection. *Virology* 2013;10:359.
- Chan KH, Poon LL, Cheng VC, Guan Y, Hung IF, Kong J, et al. Detection of SARS coronavirus in patients with suspected SARS. *Emerg Infect Dis* 2004;10:294–9.
- Faure E, Poissy J, Goffard A, Fournier C, Kipnis E, Titecat M, et al. Distinct immune response in two MERS-CoV-infected patients: can we go from bench to bedside? *PLoS ONE* 2014;9:e88716.
- de Wilde AH, Raj VS, Oudshoorn D, Bestebroer TM, van Nieuwkoop S, Limpens RW, et al. MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-alpha treatment. *J Gen Virol* 2013;94:1749–60.
- Josset L, Menachery VD, Gralinski LE, Agnihotram S, Sova P, Carter VS, et al. Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus. *mBio* 2013;4, e00165–13.